Tempus AI

“Tempus AI (Nasdaq: TEM) agreed to buy Personalis (Nasdaq: PSNL), a Fremont, Calif.-based cancer genomics company, for $1.7b.”

“Tempus, a healthcare-focused AI company, agreed to acquire Personalis, which offers personalized testing for cancer management, in a $1.25 billion deal.”

“By 2025, they had accumulated 45 million patient records across more than 400 petabytes of data. Revenue was growing at roughly 85% year-over-year... Every additional test expands the dataset in ways that improve diagnostic models.”